<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management of mushroom poisoning (except amatoxin-containing mushrooms)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management of mushroom poisoning (except amatoxin-containing mushrooms)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management of mushroom poisoning (except amatoxin-containing mushrooms)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy J Wiegand, MD, FACMT, FAACT, DFASAM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michele M Burns, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 30, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H10900927">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic discusses the management of mushroom poisoning. The clinical manifestations and evaluation of mushroom poisoning and more detailed discussion of diagnosis and treatment of poisoning with amatoxin-containing mushrooms are discussed in greater detail separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13893.html" rel="external">
          "Amatoxin-containing mushroom poisoning (eg, Amanita phalloides): Clinical manifestations, diagnosis, and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1010952633">
         <span class="h1">
          APPROACH TO MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ingestion of potentially poisonous mushrooms occurs frequently, but serious toxicity is uncommon [
         <a href="#rid1">
          1
         </a>
         ]. There are 12 groups of identified mushroom toxins with 14 described clinical syndromes  (
         <a class="graphic graphic_table graphicRef77875" href="/z/d/graphic/77875.html" rel="external">
          table 1
         </a>
         ). Defining which clinical syndrome predominates, initiating general supportive care, and administering any specific treatments for that syndrome are the key steps in the initial management for mushroom ingestion [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Supportive care and gastrointestinal decontamination with activated charcoal suffice for proper management of most patients with mushroom poisoning [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Patients who ingest potentially lethal mushrooms (eg,
         <em>
          Amanita virosa
         </em>
         ,
         <em>
          Amanita phalloides
         </em>
         ,
         <em>
          Cortinarius orellanus
         </em>
         ,
         <em>
          Gyromitra esculenta
         </em>
         ) typically develop signs of toxicity more than six hours after ingestion [
         <a href="#rid2">
          2,4
         </a>
         ]. However, clinical manifestations of poisoning that occur less than six hours after ingestion do not exclude the potential for life-threatening toxicity, especially when more than one type of mushroom has been eaten. When specific therapy is necessary, it is guided by clinical presentation  (
         <a class="graphic graphic_table graphicRef77875" href="/z/d/graphic/77875.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Mushroom poisoning syndromes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Mushroom identification'
         </a>
         .)
        </p>
        <p>
         A regional poison control center should be contacted to discuss likely mushroom species ingested based upon clinical findings, identification of any mushrooms available for analysis, and treatment of specific toxic effects. Most poison control centers maintain active call lists of mycologists who are knowledgeable concerning local prevalence of mushroom genera and species and can assist in mushroom identification. (See
         <a class="local">
          'Additional resources'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H20098225">
         <span class="h1">
          SUPPORTIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recommendations for care of children and adults with mushroom poisoning are primarily derived from case series and reports and are driven by physical findings. After initial assessment and support of airway, breathing, and circulation as needed, the clinician should anticipate and aggressively manage fluid losses caused by vomiting and diarrhea, which are common findings after toxic mushroom ingestion. The clinician should also be ready to treat symptoms caused by any of the toxic mushrooms  (
         <a class="graphic graphic_table graphicRef77875" href="/z/d/graphic/77875.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Mushroom poisoning syndromes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H77805766">
         <span class="h1">
          GASTROINTESTINAL DECONTAMINATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend that patients who are alert and present for care within one hour of a potentially toxic mushroom ingestion receive activated charcoal (AC). The recommendation of AC administration following toxic mushroom exposure derives from indirect evidence of benefit in volunteers and in animal studies, as well as from evidence of benefit following ingestions of other medications. Mushrooms, like most complex xenobiotics, bind well to AC. Because of adverse effects, such as vomiting and volume depletion, the combination of a cathartic (eg,
         <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">
          sorbitol
         </a>
         ) and AC should be used sparingly, if at all, and only a single dose of a cathartic should ever be given to any patient. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Cathartics'
         </a>
         .)
        </p>
        <p>
         The greatest benefit occurs if AC is given within one hour. The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Evidence of efficacy and adverse effects'
         </a>
         .)
        </p>
        <p>
         We recommend that patients who ingest potentially toxic mushrooms
         <strong>
          not
         </strong>
         undergo gastric emptying by gastric lavage or syrup of ipecac in the emergency department. Syrup of ipecac administered in remote locations far from medical treatment soon after pediatric ingestion may prevent toxicity [
         <a href="#rid5">
          5
         </a>
         ]. Most serious mushroom poisonings are only detected hours after ingestion, and exploratory ingestions by children typically consist of small ingestions that rarely have serious consequences [
         <a href="#rid5">
          5
         </a>
         ]. Furthermore, randomized controlled trials show minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Indications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Syrup of Ipecac'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2518884053">
         <span class="h1">
          ELIMINATION ENHANCEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple dose activated charcoal (MDAC) does not appear to improve poisoning outcomes after ingestion of mushrooms other than amatoxin-containing mushrooms. The use of MDAC for management of poisoning after ingestion of amatoxin-containing mushrooms is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13893.html" rel="external">
          "Amatoxin-containing mushroom poisoning (eg, Amanita phalloides): Clinical manifestations, diagnosis, and treatment", section on 'Management'
         </a>
         .)
        </p>
        <p>
         Hemodialysis or hemoperfusion do
         <strong>
          not
         </strong>
         remove significant amounts of mushroom toxins.
        </p>
        <p class="headingAnchor" id="H1577547991">
         <span class="h1">
          SPECIFIC CLINICAL SYNDROMES
         </span>
        </p>
        <p class="headingAnchor" id="H1129419">
         <span class="h2">
          Vomiting and diarrhea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vomiting and diarrhea may be caused by any of the toxic mushrooms and can also occur when certain edible species are not cooked prior to eating (Morchella species in particular) [
         <a href="#rid2">
          2-4,6
         </a>
         ].
        </p>
        <p>
         Vomiting may be safely treated with an antiemetic (eg,
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         0.15 mg/kg intravenously) and does not increase the amount of absorbed toxin. Antispasmodic agents (eg,
         <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">
          loperamide
         </a>
         ) should be avoided in patients with diarrhea. Intravenous fluids should be given based upon clinical assessment of losses and evidence of dehydration. Patients with signs of shock should receive prompt fluid resuscitation  (
         <a class="graphic graphic_algorithm graphicRef129655" href="/z/d/graphic/129655.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">
          "Treatment of severe hypovolemia or hypovolemic shock in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6397.html" rel="external">
          "Shock in children in resource-abundant settings: Initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2296.html" rel="external">
          "Maintenance and replacement fluid therapy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">
          "Treatment of hypovolemia (dehydration) in children in resource-abundant settings"
         </a>
         ).
        </p>
        <p>
         If more serious mushroom poisoning cannot be excluded, patients should undergo initial baseline laboratory testing and be admitted for 24 to 48 hours to rule out progression to more serious conditions (eg, liver failure, renal failure). (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Ancillary studies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Delayed symptom onset (&gt;6 hours after ingestion)'
         </a>
         and
         <a class="local">
          'Disposition'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3353206376">
         <span class="h2">
          Disulfiram-like reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vomiting, headache, flushing, pruritus, chest pain, palpitations, tachypnea, confusion, and anxiety can occur with coingestion of coprine-containing mushrooms and ethanol. The onset of symptoms is rapid, occurring within hours of drinking ethanol. It can also occur when ethanol is consumed days after the mushroom is ingested because coprine has prolonged duration of action since its metabolites irreversibly inhibit aldehyde dehydrogenase. (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Disulfiram-like reaction'
         </a>
         .)
        </p>
        <p>
         Patients suspected to have a disulfiram reaction and who have chest pain require evaluation for myocardial infarction and other serious etiologies. (See
         <a class="medical medical_review" href="/z/d/html/288.html" rel="external">
          "Evaluation of the adult with chest pain in the emergency department"
         </a>
         .)
        </p>
        <p>
         Disulfiram reactions are self-limited and managed with supportive care. The severity and duration of the reaction depends upon the amount of ethanol ingested and can last for several hours but as long as one day. Supportive therapies include the following [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vomiting –
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          Ondansetron
         </a>
         ; avoid
         <a class="drug drug_general" data-topicid="9820" href="/z/d/drug information/9820.html" rel="external">
          promethazine
         </a>
         or
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          metoclopramide
         </a>
         , which may worsen hypotension
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Orthostatic hypotension/shock – Trendelenburg positioning and boluses of crystalloid solution (eg, 1 L normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or
         <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">
          lactated Ringer
         </a>
         ); continuous infusion of
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         if hypotension is unresponsive to fluid therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin flushing and pruritus –
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          Diphenhydramine
         </a>
        </p>
        <p>
        </p>
        <p>
         Some experts would administer
         <a class="drug drug_general" data-topicid="8633" href="/z/d/drug information/8633.html" rel="external">
          fomepizole
         </a>
         (4-methylpyrazole) to a patient who develops a serious or life-threatening disulfiram reaction (severe, persistent vomiting; chest pain; or shock) and has a detectable serum ethanol concentration. Fomepizole inhibits alcohol dehydrogenase and prevents the metabolism of ethanol to acetaldehyde. Small case series have found that fomepizole reversed severe disulfiram reactions in patients with co-ingestion of disulfiram and ethanol, including those with nonspecific electrocardiogram (ECG) changes and chest pain and those with hypotension unresponsive to fluid administration and
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         [
         <a href="#rid8">
          8-10
         </a>
         ]. Although not specifically studied for co-ingestion of coprine and ethanol, the positive evidence for disulfiram and ethanol co-ingestion can be extrapolated to this scenario since coprine and disulfiram have a similar pharmacologic mechanism of action.
        </p>
        <p class="headingAnchor" id="H1129426">
         <span class="h2">
          Agitation, delirium, and/or hallucinations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Central nervous system (CNS) excitation with hallucinations may occur after ingestion of mushrooms that contain psilocybin, psilocin, muscimol, or ibotenic acid [
         <a href="#rid2">
          2,11-13
         </a>
         ]. Patients with these findings should initially receive benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         0.05 mg/kg, typical maximum single dose 2 mg or
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         0.05 to 0.1 mg/kg, typical maximum single dose 2 to 4 mg) and be placed in a quiet room. In some cases, physical restraints may also be necessary.
         <a class="drug drug_general" data-topicid="9770" href="/z/d/drug information/9770.html" rel="external">
          Physostigmine
         </a>
         should be avoided since CNS excitation is not caused by anticholinergic effects. (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Hallucinations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'CNS excitation and depression'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/317.html" rel="external">
          "Intoxication from LSD and other common hallucinogens", section on 'Agitation and dysphoria'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1129433">
         <span class="h2">
          Seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seizures are associated with ingestion of mushrooms that contain gyromitrin, or in children, muscimol or ibotenic acid [
         <a href="#rid5">
          5,14
         </a>
         ]. Initial treatment includes oxygenation, support of airway and breathing, and administration of benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         0.05 to 0.1 mg/kg, typical maximum single dose 2 to 4 mg)  (
         <a class="graphic graphic_table graphicRef55368" href="/z/d/graphic/55368.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef74649" href="/z/d/graphic/74649.html" rel="external">
          algorithm 2
         </a>
         ).
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          Pyridoxine
         </a>
         (eg, 70 mg/kg intravenously up to 5 g) should be given to patients with possible ingestion of gyromitrin-containing mushrooms and patients with unknown mushroom ingestion whose seizures are not controlled with standard anticonvulsant therapy including benzodiazepines [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Delayed gastroenteritis, seizures, and liver toxicity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'CNS excitation and depression'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1129440">
         <span class="h2">
          Cholinergic excess
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cholinergic symptoms include vomiting, diarrhea, salivation, bronchorrhea, bronchospasm, and bradycardia [
         <a href="#rid15">
          15
         </a>
         ]. Treatment consists of administration of anticholinergic medications until drying of respiratory secretions has occurred (eg, in adults,
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         1 to 2 mg intravenously; in children, 0.02 mg/kg intravenously up to single dose maximum of 2 mg, or
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         10 mcg/kg intravenously, typical maximum single dose: 0.2 mg). (See
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Atropine'
         </a>
         .)
        </p>
        <p>
         Persistent vomiting may be treated with
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         (eg, 0.1 mg/kg intravenously, maximum typical single dose 4 mg).
        </p>
        <p>
         Bronchospasm may be treated with inhaled
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         combined with
         <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">
          ipratropium
         </a>
         bromide using typical dosing for children  (
         <a class="graphic graphic_table graphicRef134102" href="/z/d/graphic/134102.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef53629" href="/z/d/graphic/53629.html" rel="external">
          table 4
         </a>
         ) and adults  (
         <a class="graphic graphic_table graphicRef54125" href="/z/d/graphic/54125.html" rel="external">
          table 5
         </a>
         ). Intravenous fluids should be given based upon clinical assessment of losses and evidence of dehydration. Patients with signs of shock should receive prompt fluid resuscitation  (
         <a class="graphic graphic_algorithm graphicRef129655" href="/z/d/graphic/129655.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Cholinergic poisoning'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">
          "Treatment of severe hypovolemia or hypovolemic shock in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6397.html" rel="external">
          "Shock in children in resource-abundant settings: Initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2296.html" rel="external">
          "Maintenance and replacement fluid therapy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">
          "Treatment of hypovolemia (dehydration) in children in resource-abundant settings"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1129447">
         <span class="h2">
          Rhabdomyolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with rhabdomyolysis typically present with the triad of pigmented granular casts in the urine, a red to brown color of the urine supernatant, and a marked elevation in the plasma creatine kinase (CK) concentration one to three days after eating the mushroom
         <em>
          Tricholoma equestre
         </em>
         [
         <a href="#rid16">
          16
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Delayed rhabdomyolysis'
         </a>
         ).
        </p>
        <p>
         A more rapid-onset rhabdomyolysis has been associated with ingestion of certain Russula species of mushroom (
         <em>
          Russula
         </em>
         subnigricans). In addition to fatigue and muscle weakness, elevation of the CK can occur within hours in some patients who ingest these mushrooms, although delayed rhabdomyolysis has been reported as well [
         <a href="#rid17">
          17
         </a>
         ]. It is thought that the toxin cyclprop-2-ene carboxylic acid is the causative agent for the myotoxic Russula species.
        </p>
        <p>
         The primary treatment goals are similar to rhabdomyolysis from other causes and are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">
          "Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluid repletion with normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion (20 to 40 mL/kg per hour up to 1 to 2 L per hour) – The emergency provider should closely monitor urine output with the goal of maintaining a minimum urine flow of 4 mL/kg per hour; 200 mL per hour in adults. Alkalinization of the urine or the use of
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         to increase diuresis may be associated with adverse effects and the efficacy of these strategies is uncertain. (See
         <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">
          "Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)", section on 'Bicarbonate in selected patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">
          "Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)", section on 'Mannitol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation for significant electrolyte abnormalities (hyperkalemia, hyperphosphatemia, and hypocalcemia) – Management of hyperkalemia is of particular importance. Hypocalcemia is usually transient and calcium administration should be avoided unless severe symptoms (eg, tetany) are present. (See
         <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">
          "Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)", section on 'Metabolic abnormalities'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1129454">
         <span class="h2">
          Liver failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who have evidence of liver toxicity or who develop signs of delayed gastroenteritis or seizures after mushroom ingestion have a high risk of developing acute liver failure caused by amatoxin- or gyromitrin-containing mushrooms. (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Delayed gastroenteritis and liver toxicity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Delayed gastroenteritis, seizures, and liver toxicity'
         </a>
         .)
        </p>
        <p>
         Early consultation with a regional poison control center is strongly encouraged. Initial management consists of intensive fluid resuscitation if hypovolemic shock is present, initiation of elimination enhancement with multiple-dose activated charcoal, and supportive care of liver toxicity. (See
         <a class="medical medical_review" href="/z/d/html/13893.html" rel="external">
          "Amatoxin-containing mushroom poisoning (eg, Amanita phalloides): Clinical manifestations, diagnosis, and treatment", section on 'Symptomatic (gastroenteritis, delayed hepatotoxicity)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3570.html" rel="external">
          "Acute liver failure in adults: Management and prognosis"
         </a>
         .)
        </p>
        <p>
         Because of the complexities involved, patients with acute liver failure should be managed in an intensive care unit in centers with an active liver transplant program. Patients admitted to hospitals without a transplant program should be transferred as soon as possible and ideally before the onset of the severe coagulopathy and increased intracranial pressure that may make later transfer dangerous.
        </p>
        <p class="headingAnchor" id="H1129461">
         <span class="h2">
          Renal failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Delayed renal insufficiency is associated with ingestion of mushrooms that contain orellanine or allenic norleucine [
         <a href="#rid18">
          18,19
         </a>
         ]. The major complications of renal failure include volume overload, hyperkalemia, metabolic acidosis, hypocalcemia, and hyperphosphatemia. The initial assessment therefore includes the careful evaluation of volume status and measurement of serum electrolytes, particularly potassium and bicarbonate, and evaluation of a complete blood count and serum phosphate, calcium, albumin and uric acid. (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Acute gastroenteritis and delayed renal failure'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Delayed renal failure'
         </a>
         .)
        </p>
        <p>
         Accepted indications for dialysis in patients with renal failure generally include (see
         <a class="medical medical_review" href="/z/d/html/1927.html" rel="external">
          "Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluid overload that is refractory to diuretics
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperkalemia (serum potassium concentration &gt;6.5 mEq/L) or rapidly rising serum potassium, as can occur in rhabdomyolysis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metabolic acidosis (arterial pH less than 7.1)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Signs of uremia, such as pericarditis, neuropathy, or an otherwise unexplained decline in mental status
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H374522997">
         <span class="h2">
          Erythromelalgia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Erythromelalgia is characterized by burning pain, swelling, and reddening or flushing in the extremities. Ingestion of Clitocybe species including
         <em>
          acromelalga
         </em>
         and
         <em>
          amoenolens
         </em>
         has been associated with the development of erythromelalgia. (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Erythromelalgia'
         </a>
         .)
        </p>
        <p>
         Treatment consists of supportive care (eg, elevation of the extremities to reduce edema) and pain control. One case of rapid improvement in pain and erythema after intravenous and oral nicotinic acid therapy has been described [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4264318813">
         <span class="h2">
          Shitake dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dermatitis is characterized by pruritic, erythematous, flagellate eruptions on either the trunk or the extremities 2 hours to 5 days after ingestion of raw or undercooked shitake mushrooms (
         <em>
          Lentinula edodes
         </em>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Shiitake dermatitis'
         </a>
         .)
        </p>
        <p>
         Treatment is supportive. Corticosteroids and antihistamines can be used in severe cases.
        </p>
        <p class="headingAnchor" id="H1538161158">
         <span class="h2">
          Immune-mediated hemolytic anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Care is supportive and includes treatment of shock, transfusion for low hemoglobin and bleeding, and management of intravascular hemolysis and organ injury, primarily kidney and liver failure. Plasmapheresis has been proposed for severe cases [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1457979">
         <span class="h1">
          ANTIDOTES
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most mushroom poisonings, supportive care is the main treatment. However, specific antidotes are available for some mushroom poisonings and may be helpful for patients with seizures and delayed gastroenteritis, methemoglobinemia, cholinergic excess, or severe disulfiram reactions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who have ingested mushrooms that contain gyromitrin and who develop seizures should receive
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         (70 mg/kg, maximum dose: 5 g) in addition to standard anticonvulsant therapy (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         )  (
         <a class="graphic graphic_algorithm graphicRef74649" href="/z/d/graphic/74649.html" rel="external">
          algorithm 2
         </a>
         ). This therapy reverses pyridoxal-5-phosphate deficiency in the CNS mediated by the toxic metabolite, monomethylhydrazine [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Seizures'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Delayed gastroenteritis, seizures, and liver toxicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who develop methemoglobinemia after consumption of mushrooms that contain gyromitrin may benefit from the administration of
         <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">
          methylene blue
         </a>
         (1 to 2 mg/kg slowly infused over five minutes) if methemoglobin is above 20 percent or causing symptoms. (See
         <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">
          "Methemoglobinemia", section on 'Management (acquired/toxic)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with evidence of cholinergic excess and respiratory distress should receive anticholinergic agents (eg,
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         intravenously, 0.02 mg/kg intravenously, minimum single dose: 0.1 mg, typical maximum single dose: 1 mg, or
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         10 mcg/kg intravenously, typical maximum single dose: 0.2 mg). (See
         <a class="local">
          'Cholinergic excess'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16135.html" rel="external">
          "Clinical manifestations and evaluation of mushroom poisoning", section on 'Cholinergic poisoning'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Atropine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some experts would administer
         <a class="drug drug_general" data-topicid="8633" href="/z/d/drug information/8633.html" rel="external">
          fomepizole
         </a>
         (15 mg/kg intravenously) to patients with suspected serious or life-threatening disulfiram reactions (severe, persistent vomiting; chest pain; or shock) with a detectable serum ethanol concentration after ingestion of coprine-containing mushrooms. (See
         <a class="local">
          'Disulfiram-like reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1458107">
         <span class="h1">
          DISPOSITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Consultation with a regional or international poison control center is advised to assist with disposition decisions. (See
         <a class="local">
          'Additional resources'
         </a>
         below.)
        </p>
        <p>
         The following patients warrant hospital admission [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with delayed symptoms more than six hours after mushroom ingestion
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with early symptoms less than three hours after mushroom ingestion who remain symptomatic beyond six hours despite supportive care or who ingested more than one type of mushroom
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with evidence of rhabdomyolysis, liver toxicity, or renal insufficiency
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic patients in whom ingestion of amatoxin-containing mushrooms is strongly suspected
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic patients in whom follow-up at 24 hours cannot be assured
        </p>
        <p>
        </p>
        <p>
         Asymptomatic patients in whom evaluation at 24 hours is assured may be discharged. Patients with early symptoms that resolve and in whom the ingestion of delayed toxicity mushrooms can be reliably excluded based upon history, clinical manifestations, and when possible, mushroom identification, may also be discharged with follow-up by phone or in person at 24 hours.
        </p>
        <p class="headingAnchor" id="H10901487">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H2869548508">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10901471">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach
         </strong>
         – Mushroom poisoning occurs frequently, but serious toxicity is uncommon. In most cases, the specific species of mushroom consumed is unknown. Classification of poisoning based upon clinical presentation  (
         <a class="graphic graphic_table graphicRef77875" href="/z/d/graphic/77875.html" rel="external">
          table 1
         </a>
         ) is most helpful in guiding further treatment and more quickly arrives at the type of mushroom ingested in most instances. A regional poison control center should be contacted to help determine likely mushroom species ingested based upon clinical findings, identification of any mushrooms available for analysis, and treatment of specific toxic effects. (See
         <a class="local">
          'Approach to management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – After careful assessment and support of airway, breathing, and circulation as needed, the clinician should anticipate and aggressively manage fluid losses caused by vomiting and diarrhea, which are common findings after toxic mushroom ingestion. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal decontamination
         </strong>
         – In an alert patient who presents for care within one hour of a potentially toxic mushroom ingestion, we recommend treatment with activated charcoal (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Gastrointestinal decontamination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a patient who ingests a potentially toxic mushroom, we recommend they
         <strong>
          not
         </strong>
         undergo gastric emptying by gastric lavage or syrup of ipecac in the emergency department (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Gastrointestinal decontamination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific clinical syndromes
         </strong>
         – The table  (
         <a class="graphic graphic_table graphicRef77875" href="/z/d/graphic/77875.html" rel="external">
          table 1
         </a>
         ) presents the specific clinical syndromes of mushroom poisoning and their treatment. (See
         <a class="local">
          'Specific clinical syndromes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antidotes
         </strong>
         – Specific antidotes are available for some mushroom poisonings and may be helpful for patients with seizures and delayed gastroenteritis, methemoglobinemia, or cholinergic excess (see
         <a class="local">
          'Antidotes'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Seizures from gyromitrin – Treat with
         <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">
          pyridoxine
         </a>
         (70 mg/kg, maximum dose: 5 g) in addition to standard anticonvulsant therapy (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         )  (
         <a class="graphic graphic_algorithm graphicRef74649" href="/z/d/graphic/74649.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Seizures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Methemoglobinemia from gyromitrin – Treat with
         <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">
          methylene blue
         </a>
         (1 to 2 mg/kg slowly infused over five minutes) if methemoglobin is above 20 percent or causing symptoms. (See
         <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">
          "Methemoglobinemia", section on 'Management (acquired/toxic)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cholinergic excess and respiratory distress –
         <strong>
         </strong>
         Treat with anticholinergic agents (eg,
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         0.02 mg/kg intravenously, minimum single dose: 0.1 mg, typical maximum single dose: 1 mg; or
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         10 mcg/kg intravenously, typical maximum single dose: 0.2 mg). (See
         <a class="local">
          'Cholinergic excess'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Disulfiram reaction - Some experts would administer
         <a class="drug drug_general" data-topicid="8633" href="/z/d/drug information/8633.html" rel="external">
          fomepizole
         </a>
         (15 mg/kg intravenously) to a patient with suspected serious or life-threatening disulfiram reaction (severe, persistent vomiting; chest pain; or shock) with a detectable serum ethanol concentration after ingestion of coprine-containing mushrooms. (See
         <a class="local">
          'Disulfiram-like reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disposition
         </strong>
         – The following patients warrant hospital admission (see
         <a class="local">
          'Disposition'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with delayed symptoms more than six hours after mushroom ingestion
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with early symptoms less than three hours after mushroom ingestion who remain symptomatic beyond six hours despite supportive care or who ingested more than one type of mushroom
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with evidence of rhabdomyolysis, liver toxicity, or renal insufficiency
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asymptomatic patients in whom ingestion of amatoxin-containing mushrooms is strongly suspected
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asymptomatic patients in whom follow-up at 24 hours cannot be assured
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.
          </a>
         </li>
         <li class="breakAll">
          Goldfrank LR. Mushrooms. In: Goldfrank's Toxicologic Emergencies, 9th ed, Nelson LS, Lewin NA, Howland MA, et al. (Eds), McGraw-Hill, New York 2011. p.1522.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger KJ, Guss DA. Mycotoxins revisited: Part II. J Emerg Med 2005; 28:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger KJ, Guss DA. Mycotoxins revisited: Part I. J Emerg Med 2005; 28:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beuhler MC, Sasser HC, Watson WA. The outcome of North American pediatric unintentional mushroom ingestions with various decontamination treatments: an analysis of 14 years of TESS data. Toxicon 2009; 53:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz JH. Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings. Crit Care Med 2005; 33:419.
          </a>
         </li>
         <li class="breakAll">
          Gupta AK. Disulfiram and disulfiram-like reactions. In: Goldfrank's Toxicologic Emergencies, 11th, Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS (Eds), McGraw-Hill Education, 2019. p.1172.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schicchi A, Besson H, Rasamison R, et al. Fomepizole to treat disulfiram-ethanol reaction: a case series. Clin Toxicol (Phila) 2020; 58:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sande M, Thompson D, Monte AA. Fomepizole for severe disulfiram-ethanol reactions. Am J Emerg Med 2012; 30:262.e3.
          </a>
         </li>
         <li class="breakAll">
          Howland MA. Fomepizole. In: Goldfrank's Toxicologic Emergencies, 11th, Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS (Eds), McGraw Hill Education, 2019. p.1435.
         </li>
         <li class="breakAll">
          Brent J, Palmer RB. Mushrooms. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th ed, Shannon MW, Borron SW, Burns MJ (Eds), Saunders Elsevier, Philadelphia, PA 2007. p.455.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benjamin DR. Mushroom poisoning in infants and children: the Amanita pantherina/muscaria group. J Toxicol Clin Toxicol 1992; 30:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satora L, Pach D, Butryn B, et al. Fly agaric (Amanita muscaria) poisoning, case report and review. Toxicon 2005; 45:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michelot D, Toth B. Poisoning by Gyromitra esculenta--a review. J Appl Toxicol 1991; 11:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pauli JL, Foot CL. Fatal muscarinic syndrome after eating wild mushrooms. Med J Aust 2005; 182:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bedry R, Baudrimont I, Deffieux G, et al. Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med 2001; 345:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trakulsrichai S, Jeeratheepatanont P, Sriapha C, et al. Myotoxic Mushroom Poisoning in Thailand: Clinical Characteristics and Outcomes. Int J Gen Med 2020; 13:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           West PL, Lindgren J, Horowitz BZ. Amanita smithiana mushroom ingestion: a case of delayed renal failure and literature review. J Med Toxicol 2009; 5:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danel VC, Saviuc PF, Garon D. Main features of Cortinarius spp. poisoning: a literature review. Toxicon 2001; 39:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakajima N, Ueda M, Higashi N, Katayama Y. Erythromelalgia associated with Clitocybe acromelalga intoxication. Clin Toxicol (Phila) 2013; 51:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz JH. Syndromic diagnosis and management of confirmed mushroom poisonings. Crit Care Med 2005; 33:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stöver A, Haberl B, Helmreich C, et al. Fatal Immunohaemolysis after the Consumption of the Poison Pax Mushroom: A Focus on the Diagnosis of the Paxillus Syndrome with the Aid of Two Case Reports. Diagnostics (Basel) 2019; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winkelmann M, Stangel W, Schedel I, Grabensee B. Severe hemolysis caused by antibodies against the mushroom Paxillus involutus and its therapy by plasma exchange. Klin Wochenschr 1986; 64:935.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13894 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15707814" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Mycotoxins revisited: Part II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15657006" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mycotoxins revisited: Part I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19708122" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The outcome of North American pediatric unintentional mushroom ingestions with various decontamination treatments: an analysis of 14 years of TESS data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699848" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699848" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31878796" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Fomepizole to treat disulfiram-ethanol reaction: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208769" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Fomepizole for severe disulfiram-ethanol reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208769" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Fomepizole for severe disulfiram-ethanol reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208769" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Fomepizole for severe disulfiram-ethanol reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1347320" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Mushroom poisoning in infants and children: the Amanita pantherina/muscaria group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15904689" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Fly agaric (Amanita muscaria) poisoning, case report and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1939997" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Poisoning by Gyromitra esculenta--a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15777146" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Fatal muscarinic syndrome after eating wild mushrooms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11556299" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Wild-mushroom intoxication as a cause of rhabdomyolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33235487" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Myotoxic Mushroom Poisoning in Thailand: Clinical Characteristics and Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19191214" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Amanita smithiana mushroom ingestion: a case of delayed renal failure and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11223095" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Main features of Cortinarius spp. poisoning: a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23641936" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Erythromelalgia associated with Clitocybe acromelalga intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699849" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Syndromic diagnosis and management of confirmed mushroom poisonings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31561486" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Fatal Immunohaemolysis after the Consumption of the Poison Pax Mushroom: A Focus on the Diagnosis of the Paxillus Syndrome with the Aid of Two Case Reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3784443" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Severe hemolysis caused by antibodies against the mushroom Paxillus involutus and its therapy by plasma exchange.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
